These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11523024)

  • 1. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies.
    Karp JE
    Semin Hematol; 2001 Jul; 38(3 Suppl 7):16-23. PubMed ID: 11523024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
    Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J
    Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
    Cortes J; Albitar M; Thomas D; Giles F; Kurzrock R; Thibault A; Rackoff W; Koller C; O'Brien S; Garcia-Manero G; Talpaz M; Kantarjian H
    Blood; 2003 Mar; 101(5):1692-7. PubMed ID: 12411300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
    J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
    Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
    Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
    Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
    Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyl transferase inhibitors in the treatment of breast cancer.
    Kelland LR
    Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
    Punt CJ; van Maanen L; Bol CJ; Seifert WF; Wagener DJ
    Anticancer Drugs; 2001 Mar; 12(3):193-7. PubMed ID: 11290865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
    Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer.
    Heymach JV; Johnson DH; Khuri FR; Safran H; Schlabach LL; Yunus F; DeVore RF; De Porre PM; Richards HM; Jia X; Zhang S; Johnson BE
    Ann Oncol; 2004 Aug; 15(8):1187-93. PubMed ID: 15277257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
    J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyl transferase inhibitors in myeloid malignancies.
    Lancet JE; Karp JE
    Blood Rev; 2003 Sep; 17(3):123-9. PubMed ID: 12818222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
    End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
    Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome.
    Kurzrock R; Cortes J; Kantarjian H
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):20-4. PubMed ID: 12447848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
    Kurzrock R; Albitar M; Cortes JE; Estey EH; Faderl SH; Garcia-Manero G; Thomas DA; Giles FJ; Ryback ME; Thibault A; De Porre P; Kantarjian HM
    J Clin Oncol; 2004 Apr; 22(7):1287-92. PubMed ID: 15051776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of clinical trials of farnesyltransferase inhibitors.
    Karp JE; Kaufmann SH; Adjei AA; Lancet JE; Wright JJ; End DW
    Curr Opin Oncol; 2001 Nov; 13(6):470-6. PubMed ID: 11673687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias.
    Lancet JE; Rosenblatt JD; Karp JE
    Semin Hematol; 2002 Jul; 39(3 Suppl 2):31-5. PubMed ID: 12214291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.